The Effect of the Nutraceutical (-)- Epicatechin on Myosteatosis in Patients With Advanced CKD

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age60+
SponsorKarolinska Institutet

About this trial

Some foods have components that can prevent and treat some diseases and provide beneficial effects for health. These components naturally occurring in foods are called nutraceuticals. Recently, it was found that Epicatechin, which is a kind of nutraceutical from the Catechin's family naturally occurring in green tea and cocoa, has positive effects on muscle mass and strength of people with chronic diseases.

People with chronic kidney disease often present muscle loss and lack of strength that are not easily treated with regular diet and physical activity. We here propose a study where 10 individuals with chronic kidney disease will receive a dose of Epicatechin for 8 weeks and we aim to test if Epicatechin improves general muscle health. Based on what is known, we expect to see an increase in muscle mass and strength.

The dose of Epicatechin provided (100 mg/day) is safe, since it is much lower than the dose usually available in supplements. In addition, this is the form naturally present in green tea and cocoa and in similar amounts. Subjects participating in the study will be evaluated for muscle mass and strength three times during the study. Muscle mass and muscle quality will be evaluated by ultrasound and magnetic resonance imaging. The participants will also perform some tests like walking in a corridor and seating and standing from a chair to measure their strength and performance. Adverse side effects will be monitored via telephone, and safety will be assessed by monthly blood tests that will evaluate liver and kidney function. If this study shows that Epicatechin can promote muscle growth and strength, it will positively affect patients with chronic kidney disease that might benefit of a natural substance from food to improve muscle health.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

estimated glomerular filtration rate (eGFR) < 29 ml/min/1.75m2

no chronic or acute known liver disease

not intended to initiate renal replacement therapy treatment in the next 4 months according to nephrologist clinical judgment

Disqualifiers

signs of active infection

acute vasculitis

type 1 diabetes

use of steroids medication

Trial design

Design model

Crossover

Treatments tested in this trial

  • Epicatechin extract

    Dietary supplement

    In the experimental phase, patients will take 50 mg of (-)- Epicatechin twice a day for 8 weeks (total dose 100mg/day). The nutraceutical will be supplied as monodose sachets from Aayam Therapeutics.Study participants will mix the sachet powder with juice (10-20mL) in the morning 15 minutes before breakfast and in the evening 15 minutes before sleeping or 1h after dinner.

Treatment groups

10 Participants
are divided into 2 treatment groups
Group A: control phaseNo intervention 0 interventions
Group B: experimental phaseExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Epicatechin supplementation effect on myosteatosis

Myosteatosis will be evaluated by Ultrasound (US) and Magnetic resonance imaging (MRI). US: We will use a B-mode wall tracking US device (Clarius, Vancouver, Canada).Two muscles will be identified, the rectus femoris and vastus intermedius. The collected images will allow us to measure muscle thickness, rectus femoris cross-sectional area, rectus femoris and vastus intermedius echogenicity. While thickness and cross-sectional area provide information on muscle quantity, the echogenicity of the muscle provides information on myosteatosis. MRI: We will evaluate rectus femoris volume, rectus femoris and vastus intermedius thickness, and rectus femoris cross-sectional area to evaluate muscle quantity. Myosteatosis will be evaluated by applying quantitative fat water imaging (Dixon imaging), information on intermuscular adipose tissue (IMAT), intramuscular adipose tissue, and average myosteatosis level will be performed by experienced radiologist.

Time frame
At enrolment, at 8 weeks from enrolment and at 16 weeks from enrolment.
2

Epicatechin supplementation effect on muscle function

Functional tests: Strength will be assessed by handgrip strength using a portable dynamometer, and by the chair stand test (5 time sit to stand and 30 seconds sit-to stand test). Performance will be assessed by the gait speed test, that evaluates the normal speed that a person usually walks and by the 6 minutes walking distance test. An integrated functional test called Short Physical Performance Battery (SPPB), will be used (at baseline, week 8 and week 16).

Time frame
At enrolment, at 8 weeks from enrolment and at 16 weeks from enrolment.

Secondary outcomes

1

Epicatechin supplementation effect on markers of muscle regeneration

We will evaluate the following blood markers that are indicators of muscle regeneration: myostatin, follistatin and GDF-11.

Time frame
At enrolment, at 8 weeks from enrolment and at 16 weeks from enrolment.
2

Epicatechin supplementation effect on markers of mitochondrial dysfunction

Mitochondrial dysfunction will be evaluated by applying the following blood markers: lactate, pyruvate, mitochondrial copy numbers, creatine phosphokinase, FGF-21, GDF-15.

Time frame
At enrolment, at 8 weeks from enrolment and at 16 weeks from enrolment.

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.